PTO/SB/08b (02-09)

Approved for use through 03/31/2009, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

s	Substitute for form 1449/PTO			Complete if Known		
				Application Number	10/788,606-Conf. #9642	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	February 27, 2004	
				First Named Inventor	Mary E. Brunkow	
				Art Unit	1646	
	(Use as many sheets as necessary)			Examiner Name	X. Xie	
Shee	1	of	1	Attorney Docket Number	31173/40002	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	C149	Albertsen et al., "A physical map and candidate genes in the BRCA1 region on chromosome 17q12-21," <i>Nature Genetics</i> , 7:472-479 (1994).	
	C150	Balemans et al., "Localization of the Gene for Sclerosteosis to the van Buchem Disease-Gene Region on Chromosome 17q12-q21," <i>Am. J. Hum. Genet.</i> , 64:1661-1669 (1999).	
	C151	Chan et al., "Á new paradigm in the treatment of osteoporosis: Wnt pathway proteins and their antagonists," Current Opinion in Investigational Drugs, 8(4):293-298 (2007).	
	C152	Expert Opinion from Dr. Catalina Lopez-Correa, dated March 6, 2009.	
	C153	Li et al., "Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling," Jour. Bio. Chem., 280(20); 19883-19887 (2005).	
	C154	van Bezooijen et al., "Wnt but Not BMP Signaling Is Involved in the Inhibitory Action of Sclerostin on BMP-Stimulated Bone Formation," <i>J. Bone. Miner. Res.</i> 22:19-28 (2007).	
	C155	Written Submission of Eli Lilly & Company, dated March 9, 2009, Opposition to European Patent No. 1133558.	

Examiner	Date	
Signature	Considered	, , , , ,

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.